期刊
INFLAMMATORY BOWEL DISEASES
卷 18, 期 1, 页码 10-16出版社
WILEY-BLACKWELL
DOI: 10.1002/ibd.21707
关键词
Crohn's disease; inflammatory bowel disease; anti-TNFa therapy; adalimumab
资金
- American Gastroenterological Association Foundation
- Digestive Disease Research Core Center of the University of Chicago [DK42086]
- Centocor, Inc.
- Abbott Laboratories
Background: Pivotal trials for adalimumab (ADA) demonstrated effectiveness versus placebo for induction and maintenance of remission in moderate to severely active Crohn's disease (CD). Although the approved maintenance regimen in the U.S. is 40 mg subcutaneously every 14 days, some patients require dose-escalation ([DE] either an increase in the delivered dose or decrease in the interval of treatment). Our objective was to determine which patient-, disease-, and therapy-related factors were associated with DE in CD patients treated with ADA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据